nect Biopharma (US:CNTB) Globenewswire·2026-02-19 14:00Company Overview - Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, particularly asthma and COPD [3] - The company is headquartered in San Diego, California and is advancing rademikibart, a next-generation antibody targeting IL-4Rα [3] Product Development - Connect Biopharma is conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, which are areas with significant unmet medical needs [3] - The company has granted an exclusive license to Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million upon achieving certain development, regulatory, and commercial milestones [3] - Connect is also eligible to receive tiered royalties on net sales in Greater China, with rates up to low double-digit percentages [3] Upcoming Events - Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 2:40 p.m. ET [1] - A live webcast of the presentation will be available on the company's investor website, with an archived replay accessible for approximately 90 days following the conference [2]